CYCLO THERAPEUTICS INC (CYTH)
US23254X2018 - Common Stock
CYTH gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While CYTH seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, CYTH is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
CYTH had negative earnings in the past year.
In the past year CYTH has reported a negative cash flow from operations.
In the past 5 years CYTH always reported negative net income.
In the past 5 years CYTH always reported negative operating cash flow.
1.2 Ratios
CYTH has a worse Return On Assets (-151.45%) than 86.84% of its industry peers.
Looking at the Return On Equity, with a value of -421.77%, CYTH is doing worse than 78.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -151.45% | ||
| ROE | -421.77% | ||
| ROIC | N/A |
ROA(3y)-196.91%
ROA(5y)-167.39%
ROE(3y)-876.42%
ROE(5y)-703.18%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CYTH has a Gross Margin of 90.71%. This is amongst the best in the industry. CYTH outperforms 93.50% of its industry peers.
CYTH's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CYTH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.5%
GM growth 5Y0.39%
2. Health
2.1 Basic Checks
CYTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
CYTH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CYTH has more shares outstanding
CYTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -10.99, we must say that CYTH is in the distress zone and has some risk of bankruptcy.
CYTH's Altman-Z score of -10.99 is on the low side compared to the rest of the industry. CYTH is outperformed by 78.46% of its industry peers.
CYTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.99 |
ROIC/WACCN/A
WACC9.23%
2.3 Liquidity
CYTH has a Current Ratio of 1.45. This is a normal value and indicates that CYTH is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.45, CYTH is not doing good in the industry: 84.44% of the companies in the same industry are doing better.
CYTH has a Quick Ratio of 1.42. This is a normal value and indicates that CYTH is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.42, CYTH is doing worse than 83.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.45 | ||
| Quick Ratio | 1.42 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 26.80% over the past year.
CYTH shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -21.40%.
CYTH shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.28% yearly.
EPS 1Y (TTM)26.8%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q56.79%
Revenue 1Y (TTM)-21.4%
Revenue growth 3Y6.15%
Revenue growth 5Y1.28%
Revenue growth Q2Q63.89%
3.2 Future
The Earnings Per Share is expected to grow by 34.93% on average over the next years. This is a very strong growth
CYTH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 323.57% yearly.
EPS Next Y32.69%
EPS Next 2Y34.93%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year100%
Revenue Next 2Y323.57%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CYTH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CYTH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CYTH's earnings are expected to grow with 34.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.93%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CYTH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYCLO THERAPEUTICS INC
NASDAQ:CYTH (4/18/2024, 7:00:02 PM)
After market: 1.24 +0.04 (+3.33%)1.2
-0.01 (-0.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap34.46M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -151.45% | ||
| ROE | -421.77% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 90.71% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.45 | ||
| Quick Ratio | 1.42 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)26.8%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y32.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-21.4%
Revenue growth 3Y6.15%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y